Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients

Anesthesia with Isoflurane Increases Amyloid Pathology in Mice Models of Alzheimer'S Disease

(2017) Juan Perucho et al.   JOURNAL OF ALZHEIMERS DISEASE

Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type?

(2017) Robert G. Struble et al.   JOURNAL OF ALZHEIMERS DISEASE

Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease

(2016) Xian-Le Bu et al.   Current Alzheimer Research

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

(2016) Davide Seripa et al.   Expert Review of Neurotherapeutics

Prevention Trials in Alzheimer’s Disease: Current Status and Future Perspectives

(2016) Jun Wang et al.   JOURNAL OF ALZHEIMERS DISEASE

The amyloid cascade hypothesis: are we poised for success or failure?

(2016) Eric Karran et al.   JOURNAL OF NEUROCHEMISTRY

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

(2016) Davide Seripa et al.   Expert Review of Neurotherapeutics

Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change

(2016) Anja Soldan et al.   JAMA Neurology

2015 Alzheimer's disease facts and figures

(2015)   Alzheimers & Dementia

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

(2015) Tiia Ngandu et al.   LANCET

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions

(2015) Sandrine Andrieu et al.   LANCET NEUROLOGY

Neuroinflammation in Alzheimer's disease

(2015) Michael T Heneka et al.   LANCET NEUROLOGY

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

(2015) Erik S Musiek et al.   NATURE NEUROSCIENCE

The Alzheimer disease market

(2015) XiaoXiao Qian et al.   NATURE REVIEWS DRUG DISCOVERY

What lessons can be learned from failed Alzheimer’s disease trials?

(2015) Jeremy Toyn   Expert Review of Clinical Pharmacology

A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease

(2014) Richard Grove et al.   Current Alzheimer Research

Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?

(2014) Francesco Panza et al.   CURRENT OPINION IN PSYCHIATRY

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?

(2014) Francesco Panza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

(2014) Francesco Panza et al.   Expert Review of Clinical Immunology

Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease

(2014) Francesco Panza et al.   Expert Review of Neurotherapeutics

A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid β in the Brain in a Transgenic Model of Alzheimer Disease

(2014) Yukiko Hori et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Advances in the prevention of Alzheimer's disease and dementia

(2014) A. Solomon et al.   JOURNAL OF INTERNAL MEDICINE

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects

(2014) Robert Vassar et al.   JOURNAL OF NEUROCHEMISTRY

Targeting the β secretase BACE1 for Alzheimer's disease therapy

(2014) Riqiang Yan et al.   LANCET NEUROLOGY

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

(2014) Robert Vassar   Alzheimers Research & Therapy

The Preclinical Alzheimer Cognitive Composite

(2014) Michael C. Donohue et al.   JAMA Neurology

Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

(2013) Keith A. Johnson et al.   Alzheimers & Dementia

Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease

(2013) Carolyn W. Zhu et al.   Alzheimers & Dementia

The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease

(2013) Mark Forman et al.   Alzheimers & Dementia

Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)

(2013)   Alzheimers & Dementia

Tau-aggregation inhibitor therapy for Alzheimer's disease

(2013) Claude M. Wischik et al.   BIOCHEMICAL PHARMACOLOGY

Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?

(2013) Haythum O Tayeb et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Immunotherapy for Alzheimer’s disease: hoops and hurdles

(2013) Cynthia A Lemere   Molecular Neurodegeneration

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial

(2013) S.M. Mills et al.   REVUE NEUROLOGIQUE

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

(2013) Jens Moreth et al.   Immunity & Ageing

A tale of two drug targets: the evolutionary history of BACE1 and BACE2

(2013) Christopher Southan et al.   Frontiers in Genetics

The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration

(2012) Mark Forman et al.   Alzheimers & Dementia

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

Alzheimer Mechanisms and Therapeutic Strategies

(2012) Yadong Huang et al.   CELL

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

(2012) Bruno P Imbimbo et al.   Expert Review of Clinical Immunology

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis

(2012) Jungsu Kim et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Axonal regulation of Schwann cell ensheathment and myelination

(2012) James L. Salzer   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model

(2012) Jose Morales-Corraliza et al.   NEUROBIOLOGY OF AGING

Passive Immunization against Pyroglutamate-3 Amyloid-ß Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

(2012) Jeffrey L. Frost et al.   Neurodegenerative Diseases

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

3,3′,4′,5,5′-Pentahydroxyflavone is a potent inhibitor of amyloid β fibril formation

(2012) Hiroko Ushikubo et al.   NEUROSCIENCE LETTERS

The Serotonin-6 Receptor as a Novel Therapeutic Target

(2012) Hyung-Mun Yun et al.   Experimental Neurobiology

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Clifford R. Jack et al.   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

(2011) Victor L. Villemagne et al.   ANNALS OF NEUROLOGY

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

(2011) Clifford R. Jack et al.   ANNALS OF NEUROLOGY

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass

(2011) Daria Esterházy et al.   Cell Metabolism

Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab

(2011) Francesco Panza et al.   Current Alzheimer Research

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease

(2011) Grazia D'Onofrio et al.   Expert Opinion on Drug Discovery

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis

(2011) Petra Steinacker et al.   PLoS One

Testing the Right Target and Right Drug at the Right Stage

(2011) R. A. Sperling et al.   Science Translational Medicine

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid

(2010) V. Frisardi et al.   Current Alzheimer Research

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease

(2010) Joseph F. Quinn et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Revising the definition of Alzheimer's disease: a new lexicon

(2010) Bruno Dubois et al.   LANCET NEUROLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study

(2009) Richard C. Mohs et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Simvastatin therapy prevents brain trauma-induced increases in β-amyloid peptide levels

(2009) Eric E. Abrahamson et al.   ANNALS OF NEUROLOGY

The Common Inhalational Anesthetic Sevoflurane Induces Apoptosis and Increases β-Amyloid Protein Levels

(2009) Yuanlin Dong et al.   ARCHIVES OF NEUROLOGY

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

(2009) O L Lopez et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Oligomeric amyloid   associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

(2009) R. M. Koffie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Amyloid-Associated Depression

(2008) Xiaoyan Sun et al.   ARCHIVES OF GENERAL PSYCHIATRY

Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)

(2008)   ARCHIVES OF NEUROLOGY

Alzheimer Disease Pathology As a Host Response

(2008) Rudy J. Castellani et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

(2008) Lars Lannfelt et al.   LANCET NEUROLOGY

Protective effects of NSAIDs on the development of Alzheimer disease

(2008) Steven C. Vlad et al.   NEUROLOGY

Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid β protein

(2008) Tatsuhiro Akaishi et al.   NEUROSCIENCE LETTERS

No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial

(2008) Daniëlle de Jong et al.   PLoS One

Multiple sclerosis and Alzheimer's disease

(2007) Assunta Dal Bianco et al.   ANNALS OF NEUROLOGY